Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Helicase-like transcription factor (HLTF) is a multifunctional enzyme and chromatin remodeler belonging to the SWI/SNF family, with roles in DNA repair, transcription regulation, and protein remodeling at stalled replication forks. HLTF contains a HIRAN DNA-binding domain, a SWI/SNF-like helicase domain, and a RING finger domain conferring E3 ubiquitin ligase activity. Through its dsDNA translocase activity, HLTF orchestrates fork remodeling and regression to facilitate template-switching-based, error-free DNA damage bypass. HLTF is considered a tumor suppressor, frequently inactivated via promoter methylation or sporadic alternative splicing in colorectal and gastric cancers. Loss of HLTF function compromises cellular resistance to DNA damage and is associated with increased sensitivity to UV and genotoxic agents[1][2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Helicase-like transcription factor (HLTF).